NASDAQ:ZSAN - Zosano Pharma Stock Price, Forecast & News

Zosano Pharma trades on the NASDAQ under the ticker symbol "ZSAN."

Zosano Pharma's stock reverse split on Friday, January 26th 2018. The 1-20 reverse split was announced on Thursday, January 25th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 25th 2018. An investor that had 100 shares of Zosano Pharma stock prior to the reverse split would have 5 shares after the split.

Zosano Pharma Corp (NASDAQ:ZSAN) announced its quarterly earnings results on Thursday, November, 14th. The biotechnology company reported ($0.55) EPS for the quarter, topping analysts' consensus estimates of ($0.58) by $0.03. View Zosano Pharma's Earnings History.

Zosano Pharma is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Zosano Pharma.

3 equities research analysts have issued twelve-month price targets for Zosano Pharma's stock. Their forecasts range from $6.00 to $16.00. On average, they anticipate Zosano Pharma's share price to reach $10.00 in the next year. This suggests a possible upside of 1,251.4% from the stock's current price. View Analyst Price Targets for Zosano Pharma.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zosano Pharma in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zosano Pharma.

News coverage about ZSAN stock has been trending very positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Zosano Pharma earned a daily sentiment score of 4.0 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for Zosano Pharma.

Some companies that are related to Zosano Pharma include Alpine Immune Sciences (ALPN), Aclaris Therapeutics (ACRS), American Brivision (Holding) (ABVC), Processa Pharmaceuticals (PCSA), resTORbio (TORC), AgeX Therapeutics (AGE), Vascular Biogenics (VBLT), PLx Pharma (PLXP), Tiziana Life Sciences (TLSA), Acasti Pharma (ACST), Bellicum Pharmaceuticals (BLCM), Forward Pharma A/S (FWP), Zafgen (ZFGN), SUMMIT THERAPEU/S (SMMT) and IntelGenx Technologies (IGXT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Zosano Pharma investors own include AEterna Zentaris (AEZS), Iovance Biotherapeutics (IOVA), Idera Pharmaceuticals (IDRA), Immunomedics (IMMU), Synergy Pharmaceuticals (SGYP), Square (SQ), SCYNEXIS (SCYX), Verastem (VSTM), Protalix Biotherapeutics (PLX) and AVEO Pharmaceuticals (AVEO).

(ZSAN) raised $47 million in an initial public offering (IPO) on Tuesday, January 27th 2015. The company issued 4,300,000 shares at $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners served as the underwriters for the IPO.

Zosano Pharma's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Aisling Capital Management LP (14.91%), Alyeska Investment Group L.P. (1.89%), Banco Bilbao Vizcaya Argentaria S.A. (0.66%), FNY Investment Advisers LLC (0.55%), UBS Group AG (0.38%) and Ieq Capital LLC (0.28%). Company insiders that own Zosano Pharma stock include Amzak Capital Management, Llc and John Peter Walker. View Institutional Ownership Trends for Zosano Pharma.

ZSAN stock was sold by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P. and FNY Investment Advisers LLC. View Insider Buying and Selling for Zosano Pharma.

ZSAN stock was bought by a variety of institutional investors in the last quarter, including Aisling Capital Management LP, Banco Bilbao Vizcaya Argentaria S.A., Ieq Capital LLC, Ieq Capital LLC, Oxford Asset Management LLP and UBS Group AG. View Insider Buying and Selling for Zosano Pharma.

Shares of ZSAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ZSAN stock can currently be purchased for approximately $0.74.

Zosano Pharma has a market capitalization of $13.49 million. The biotechnology company earns $-35,360,000.00 in net income (profit) each year or ($3.74) on an earnings per share basis. Zosano Pharma employs 53 workers across the globe.View Additional Information About Zosano Pharma.

The official website for Zosano Pharma is http://www.zosanopharma.com/.

Zosano Pharma's mailing address is 34790 ARDENTECH COURT, FREMONT CA, 94555. The biotechnology company can be reached via phone at 510-745-1200 or via email at [email protected]